前药
体内
纳米医学
达沙替尼
生物相容性
药物输送
顺铂
化学
纳米颗粒
药品
体外
琥珀酸酐
结合
纳米技术
毒品携带者
药理学
材料科学
化疗
生物化学
有机化学
医学
受体
数学分析
生物
生物技术
酪氨酸激酶
数学
外科
作者
Yang Lu,Jiaxi Xu,Zheng Xie,Fei Song,Xin Wang,Rupei Tang
标识
DOI:10.1016/j.ajps.2021.08.001
摘要
Carrier-free drug self-delivery systems consisting of amphiphilic drug-drug conjugate (ADDC) with well-defined structure and nanoscale features have drawn much attention in tumor drug delivery. Herein, we report a simple and effective strategy to prepare ADDC using derivatives of cisplatin (CP) and dasatinib (DAS), which further self-assembled to form reduction-responsive nanoparticles (CP-DDA NPs). DAS was modified with succinic anhydride and then connected with CP derivative by ester bonds. The size, micromorphology and in vitro drug release of CP-DDA NPs were characterized. The biocompatibility and bioactivity of these carrier-free nanoparticles were then investigated by HepG2 cells and H22-tumor bearing mice. In vitro and in vivo experiments proved that CP-DDA NPs had excellent anti-tumor activity and significantly reduced toxicities. This study provides a new strategy to design the carrier-free nanomedicine composed of CP and DAS for synergistic tumor treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI